Amneal Pharmaceuticals: Escape from the Generics Trap

Amneal Pharmaceuticals has successfully transformed from an interchangeable mass producer of simple generic medications to a high-margin specialty and biosimilar company. With the newly launched Parkinson's drug CREXONT, a growing biosimilar pipeline, and domestic US production capacities to tackle hospital supply shortages, the company secures significant market opportunities with high pricing power. The US pharmaceutical sector has been suffering for years from a structural paradox: the government and health insurers continuously increase...